TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Interventions for Anxious Children
Brief Summary: This study will evaluate the effectiveness of school-based cognitive behavioral therapy with or without parental involvement in treating anxious children.


Options:
A: Arm Label: Social Effectiveness Therapy for Children; Type: EXPERIMENTAL; Interventions: Behavioral: Social Effectiveness Therapy for Children (SET-C) | Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Pill placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pill Placebo | Intervention Type: BEHAVIORAL; Name: Social Effectiveness Therapy for Children (SET-C); Assigned to Arm(s): Social Effectiveness Therapy for Children | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Pill Placebo; Assigned to Arm(s): Pill placebo
B: Arm Label: Cognitive-Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Wait-list; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Wait-list | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Cognitive-Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Wait-list; Assigned to Arm(s): Wait-list
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT for children plus parent training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group CBT for children; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Group CBT for children plus parent training; Assigned to Arm(s): 2
D: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease
Brief Summary: The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer disease, in the setting of concomitant aspirin therapy.

Antiplatelet therapy is an essential element of care for patients with atherothrombotic disease. Bleeding is a fundamental adverse effect of all antiplatelet drugs including aspirin, clopidogrel and dual antiplatelet regimens.

The gastrointestinal tract is the most common site of bleeding related to antiplatelet therapy, typically in connection with peptic ulcer disease. Recently published studies suggest the use of clopidogrel carries a gastrointestinal bleeding risk similar to that of aspirin or non-aspirin non-steroidal anti-inflammatory drugs. Patients taking any two of these drugs (clopidogrel, aspirin and/or non-aspirin NSAIDs) are exposed to an even higher risk of bleeding and ulcer disease.

Cogentus Pharmaceuticals is launching phase 3 trials of a novel combination product, CGT-2168, which has the potential to significantly reduce this problem and increase patient safety. CGT-2168 combines a standard dosage of clopidogrel and a gastroprotectant (omeprazole) in a once-daily pill that may reduce the likelihood of adverse gastrointestinal events.


Options:
A: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Plavix (clopidogrel 75 mg) and aspirin | Intervention Type: DRUG; Name: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Plavix (clopidogrel 75 mg) and aspirin; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole 20 mg daily | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: famotidine 40 mg daily | Intervention Type: DRUG; Name: esomeprazole 20 mg daily; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: famotidine 40 mg daily; Assigned to Arm(s): 2
D: Arm Label: Proton pump inhibitor (PPI); Type: EXPERIMENTAL; Interventions: Drug: Pantoprazole | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (0.9%) | Intervention Type: DRUG; Name: Pantoprazole; Assigned to Arm(s): Proton pump inhibitor (PPI) | Intervention Type: OTHER; Name: Saline (0.9%); Assigned to Arm(s): Normal saline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Primary Surgical Treatment on Survival in Patients With Metastatic Breast Cancer at Diagnosis
Brief Summary: Primary treatments for metastatic breast cancer are chemotherapy and radiation therapy, and surgery is reserved for tumor related complications such as bleeding. Retrospective studies showed that surgical removal of the primary tumor improves survival of patients with metastatic breast cancer at diagnosis. We hypothesis and testing that surgical removal of the primary tumor will lead to an improvement of overall survival


Options:
A: Arm Label: Loco Regional Treatment Arm (LRT); Type: EXPERIMENTAL; Interventions: Procedure: Surgery for breast cancer | Arm Label: No Loco-regional Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: No Loco-regional treatment | Intervention Type: PROCEDURE; Name: Surgery for breast cancer; Assigned to Arm(s): Loco Regional Treatment Arm (LRT) | Intervention Type: OTHER; Name: No Loco-regional treatment; Assigned to Arm(s): No Loco-regional Treatment Arm
B: Arm Label: Pertuzumab + Trastuzumab + Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Pertuzumab, Drug: Trastuzumab, Drug: Docetaxel | Arm Label: Placebo + Trastuzumab + Docetaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Trastuzumab, Drug: Docetaxel | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel
C: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: OTHER; Interventions: Procedure: Primary surgery | Intervention Type: PROCEDURE; Name: Primary surgery; Assigned to Arm(s): B
D: Arm Label: Upfront surgery; Type: EXPERIMENTAL; Interventions: Procedure: upfront breast surgery | Arm Label: Systemic therapy; Type: OTHER; Interventions: Other: systemic therapy | Intervention Type: PROCEDURE; Name: upfront breast surgery; Assigned to Arm(s): Upfront surgery | Intervention Type: OTHER; Name: systemic therapy; Assigned to Arm(s): Systemic therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maintenance of Skeletal Integrity in Frail Elders
Brief Summary: This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.


Options:
A: Arm Label: Whole Body Vibration Group; Type: EXPERIMENTAL; Interventions: Device: Vibrosphère device | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibrosphère device; Assigned to Arm(s): Whole Body Vibration Group
B: Arm Label: Mulitfaceted podiatry Intervention; Type: EXPERIMENTAL; Interventions: Other: Foot and ankle exercises, foot orthoses, footwear provision | Arm Label: Usual podiatry care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Foot and ankle exercises, foot orthoses, footwear provision; Assigned to Arm(s): Mulitfaceted podiatry Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual podiatry care
C: Arm Label: Active Medication Group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous zoledronic acid, Dietary Supplement: Vitamin D 800 IU/daily, Dietary Supplement: Calcium 1200 mg/daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Intravenous zoledronic acid, Dietary Supplement: Vitamin D 800 IU/daily, Dietary Supplement: Calcium 1200 mg/daily | Intervention Type: DRUG; Name: Intravenous zoledronic acid; Assigned to Arm(s): Active Medication Group, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 800 IU/daily; Assigned to Arm(s): Active Medication Group, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium 1200 mg/daily; Assigned to Arm(s): Active Medication Group, Placebo
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: 8-week aerobic and strength training program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 8-week aerobic and strength training program; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.
Brief Summary: The aim of the study was to assess the clinical effect of immunostimulatory enteral and parenteral nutrition in patients undergoing resection for gastrointestinal cancer. 205 subjects were randomly assigned into four study groups, standard and immunostimulating, enteral and parenteral. The study was designed to test the hypothesis that immunonutrition and enteral nutrition would reduce the incidence of infectious complications following upper gastrointestinal surgery.


Options:
A: Arm Label: Early Goal-Directed Nutrition; Type: EXPERIMENTAL; Interventions: Other: Early Goal-Directed Nutrition | Arm Label: ASPEN-guidelines; Type: ACTIVE_COMPARATOR; Interventions: Other: ASPEN-guidelines | Intervention Type: OTHER; Name: Early Goal-Directed Nutrition; Assigned to Arm(s): Early Goal-Directed Nutrition | Intervention Type: OTHER; Name: ASPEN-guidelines; Assigned to Arm(s): ASPEN-guidelines
B: Arm Label: SEN; Type: EXPERIMENTAL; Interventions: Drug: peptisorb | Arm Label: IMEN; Type: EXPERIMENTAL; Interventions: Drug: Stresson | Arm Label: SPN; Type: EXPERIMENTAL; Interventions: Drug: Parenteral nutrition | Arm Label: IMPN; Type: EXPERIMENTAL; Interventions: Drug: Omegaven, Dipeptiven | Intervention Type: DRUG; Name: peptisorb; Assigned to Arm(s): SEN | Intervention Type: DRUG; Name: Stresson; Assigned to Arm(s): IMEN | Intervention Type: DRUG; Name: Parenteral nutrition; Assigned to Arm(s): SPN | Intervention Type: DRUG; Name: Omegaven, Dipeptiven; Assigned to Arm(s): IMPN
C: Arm Label: residual gastric volume; Type: OTHER; Interventions: Procedure: monitoring of residual gastric volume | Arm Label: residual gastric volume not monitored; Type: OTHER; Interventions: Procedure: not monitoring of residual gastric volume | Intervention Type: PROCEDURE; Name: monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume | Intervention Type: PROCEDURE; Name: not monitoring of residual gastric volume; Assigned to Arm(s): residual gastric volume not monitored
D: Arm Label: SPN group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: SPN | Arm Label: Control gr; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: SPN; Assigned to Arm(s): SPN group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Overcoming Literacy Barriers in Colorectal Cancer Screening
Brief Summary: The purpose of this study is to determine whether a multimedia educational computer program can increase colorectal cancer screening rates in low and adequate literacy patients.


Options:
A: Intervention Type: PROCEDURE; Name: Educational handout about prostate cancer screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Simple cue for patient to talk to doctor; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention with Colorectal Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Colorectal Web | Intervention Type: BEHAVIORAL; Name: Colorectal Web; Assigned to Arm(s): Intervention with Colorectal Website
C: Arm Label: Internet Based Safety Decision Aid; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based safety decision aid | Arm Label: Control Website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Safety Plan | Intervention Type: BEHAVIORAL; Name: Internet-based safety decision aid; Assigned to Arm(s): Internet Based Safety Decision Aid | Intervention Type: BEHAVIORAL; Name: Usual Care Safety Plan; Assigned to Arm(s): Control Website
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: CHOICE decision aid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: YourMeds patient education program | Intervention Type: BEHAVIORAL; Name: CHOICE decision aid; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: YourMeds patient education program; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Brief Summary: The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).


Options:
A: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
B: Arm Label: Edoxaban group; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban, Drug: Low molecular weight heparin | Arm Label: Dalteparin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Edoxaban group | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin group | Intervention Type: DRUG; Name: Low molecular weight heparin; Assigned to Arm(s): Edoxaban group
C: Arm Label: Innohep®; Type: EXPERIMENTAL; Interventions: Drug: Innohep® | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Innohep®; Assigned to Arm(s): Innohep®
D: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Brief Summary: The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: Dabigatran etexilate (150mg bid); Type: EXPERIMENTAL; Interventions: Drug: Dabigatran etexilate | Arm Label: Warfarin (INR 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR 2.0-3.0) | Intervention Type: DRUG; Name: Dabigatran etexilate; Assigned to Arm(s): Dabigatran etexilate (150mg bid)
C: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: warfarin, Drug: Placebo for apixaban | Arm Label: Enoxaparin + Warfarin; Type: EXPERIMENTAL; Interventions: Drug: Placebo for enoxaparin, Drug: Placebo for warfarin, Drug: apixaban | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo for enoxaparin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: Placebo for warfarin; Assigned to Arm(s): Enoxaparin + Warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): Enoxaparin + Warfarin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Brief Summary: The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
C: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Proximal Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism.
Brief Summary: The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein thrombosis (DVT) or pulmonary embolism (PE) who completed 6 to 18 months of treatment with vitamin K antagonist (VKA).


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: GFFC + LMWH; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparine | Intervention Type: DRUG; Name: Enoxaparine; Assigned to Arm(s): GFFC + LMWH
C: Arm Label: intermittent pneumatic compression; Type: EXPERIMENTAL; Interventions: Drug: low molecular weight heparin | Intervention Type: DRUG; Name: low molecular weight heparin; Assigned to Arm(s): intermittent pneumatic compression
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: A